CG Oncology
Presence
CG Oncology is a company listed under the stock ticker CGON (US).
Acquisition, funding and merger involving CG Oncology.
- CG Oncology has filed its IPO. Its stock ticker will be CGON. (posted on January 8 2024).
- CG Oncology has just announced a $100 Million fundraising (posted on January 8 2024).
- CG Oncology has just announced a $100 Million fundraising (posted on August 3 2023).
- CG Oncology has just announced a $120 Million fundraising (posted on November 17 2022).
- See more news about CG Oncology Hide news involving CG Oncology
Executives
View the org chart displaying its 16 main executives
Most searched biographies at CG Oncology
Popular executive movements at CG Oncology
- Corleen Roche has joined the company as Chief Financial Officer (posted on January 29 2024).
- Vijay Kasturi has joined the company as Chief Medical Officer (posted on September 6 2023).
- Swapnil Bhargava has joined the company as Chief Technical Officer (posted on September 6 2023).
Click here to view some more movements at CG Oncology
Create your alert
to follow the executive moves at CG Oncology.
Biotechnology
CG Oncology has 2,294 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and Adaptive Phage Therapeutics (United States (USA)).
Popular M&A news in Biotechnology
- Lycia Therapeutics has just announced a $107 Million fundraising (posted on May 15 2024).
- Attovia Therapeutics has just announced a $150 Million fundraising (posted on May 14 2024).
- Bruker has announced the acquisition of NanoString Technologies (posted on May 13 2024).
Popular contacts in Biotechnology
News
Press releases by CG Oncology
- CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024 | CG Oncology
- CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024 | CG Oncology
- CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual Meeting | CG Oncology
- CG Oncology Announces First Patient Dosed in PIVOT-006 Phase 3 Clinical Trial of Cretostimogene in Intermediate-risk Non-Muscle Invasive Bladder Cancer | CG Oncology
- CG Oncology Announces Pricing of Upsized Initial Public Offering | CG Oncology
- Events & Conferences | CG Oncology
- CG Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares | CG Oncology
- Press Releases | CG Oncology
- GDPR Cookie Compliance (CCPA, DSGVO, Cookie Consent)
- News | Upcoming Conferences | Media Contact | CG Oncology
- View more press releases Close
Social media about CG Oncology
- CG Oncology on Wikipedia, Google News & Yahoo Finance
- CG Oncology on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Arthur Kuan 
